Bruce Goldsmith
Geen lopende functies
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Abraham Noah Oler | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 jaar |
Maxine Gowen | M | 66 | 3 jaar | |
Stuart M. Henderson | M | - | 3 jaar | |
Athena Countouriotis | M | 52 | 4 jaar | |
Bimal Shah | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 jaar |
Derrell Porter | M | 53 | 3 jaar | |
Kathleen Borthwick | F | 48 | 3 jaar | |
Ira R. Harkavy | M | 75 |
University of Pennsylvania
| 32 jaar |
Rajesh Shrotriya | M | 79 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 jaar |
Luigi Lenaz | M | 83 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 jaar |
Thomas Brock | M | 77 |
Columbia Business School
| 26 jaar |
Robert J. Borghese | M | - |
University of Pennsylvania
| 32 jaar |
Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 jaar |
James E. Shields | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 jaar |
Elizabeth E. Bailey | F | 86 |
University of Pennsylvania
| 33 jaar |
Mark Forman | M | 60 | 3 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Stephen J. Hoffman | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 18 jaar |
Stephen P. Squinto | M | 67 | 4 jaar | |
Paul Sekhri | M | 66 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 4 jaar |
Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 jaar |
David Vurgait | M | 59 |
University of Pennsylvania
| 1 jaar |
Kathleen Metters | M | 66 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 4 jaar |
Pablo Cagnoni | M | 60 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI.
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 jaar |
Kenneth Robert Marcus | M | - |
University of Pennsylvania
| 5 jaar |
Joan Midthun Larrea | F | 58 |
University of Pennsylvania
| 4 jaar |
Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 jaar |
Juan Pablo Córdoba Garcés | M | - |
University of Pennsylvania
| 5 jaar |
Shiv Vikram Khemka | M | 61 |
University of Pennsylvania
| 2 jaar |
Liam Ratcliffe | M | 60 | 3 jaar | |
Alex Abell | M | - |
University of Pennsylvania
| 4 jaar |
Scott M. Gallin | M | 51 |
University of Pennsylvania
| 5 jaar |
Helen Remeza | M | - |
University of Pennsylvania
| 5 jaar |
John W. Glomb | M | - |
University of Pennsylvania
| 12 jaar |
Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 jaar |
Darius Beni Cayetano | M | 50 |
University of Pennsylvania
| 11 jaar |
Rich Ballew | M | - |
University of Pennsylvania
| 3 jaar |
Sassan Alizadeh | M | - |
University of Pennsylvania
| 7 jaar |
Gregory Z. Rush | M | - |
University of Pennsylvania
| 4 jaar |
David Anderman | M | - |
University of Pennsylvania
| 4 jaar |
Wissam Jabre | M | 54 |
Columbia Business School
| 6 jaar |
Sanjay Kumar Sanghoee | M | - |
Columbia Business School
| 2 jaar |
Frank Mora | M | - |
Columbia Business School
University of Pennsylvania
| 7 jaar |
David Perla | M | 54 |
Colgate University
University of Pennsylvania
| 4 jaar |
Patrick Heron | M | 53 | 3 jaar | |
Timothy Patrick Lynch | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 jaar |
Peter Carlin | M | 51 |
Columbia Business School
University of Pennsylvania
| 7 jaar |
Lisa Granick | F | - |
University of Pennsylvania
| 2 jaar |
Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 jaar |
Jonathan Leff | M | 55 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 7 jaar |
Tadataka Yamada | M | 77 | 4 jaar | |
Alex Howarth | M | 55 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 4 jaar |
David Clark | M | 56 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 jaar |
David Stout | M | 69 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 jaar |
Alex Norton | M | - |
Columbia Business School
University of Pennsylvania
| 7 jaar |
Joseph Turner | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | - |
Yu Ren Wang | M | 63 |
University of Pennsylvania
| 3 jaar |
Rajeev Narang | M | - |
University of Pennsylvania
| 4 jaar |
Daniel J. Jansen | M | - |
University of Pennsylvania
| 2 jaar |
Steve A. Foreman | M | - |
University of Pennsylvania
| 4 jaar |
Seth M. Bienstock | M | - |
University of Pennsylvania
| 4 jaar |
Jeff Fluhr | M | - |
University of Pennsylvania
| 4 jaar |
Josh Weinstein | M | 49 |
University of Pennsylvania
| 4 jaar |
Eric Robert Korsten | M | - |
University of Pennsylvania
| 4 jaar |
Courtney Spaeth | F | - |
University of Pennsylvania
| 3 jaar |
Mark Yosowitz | M | 54 |
University of Pennsylvania
| 4 jaar |
Jason Ruspini | M | - |
University of Pennsylvania
| 4 jaar |
Priti Choksi | F | - |
University of Pennsylvania
| 4 jaar |
Rob Amir | M | - |
University of Pennsylvania
| 4 jaar |
Kristy Cunningham | F | - |
University of Pennsylvania
| 4 jaar |
Marc D'Olimpio | M | - |
University of Pennsylvania
| 4 jaar |
Lisa Shapiro Strovink | F | - |
University of Pennsylvania
| 4 jaar |
Brett Aukburg | M | - |
University of Pennsylvania
| 5 jaar |
Hyon C. Park | M | 51 |
University of Pennsylvania
| 4 jaar |
David Levy | M | - |
University of Pennsylvania
| 4 jaar |
Yun Chen | M | 54 |
University of Pennsylvania
| 5 jaar |
Dan E. Cromie | M | - |
University of Pennsylvania
| 4 jaar |
Katherine Lehman | F | 49 |
University of Pennsylvania
| 4 jaar |
Gregory D. Myers | M | 53 |
University of Pennsylvania
| 4 jaar |
Melanie H. Berkowitz | F | - |
University of Pennsylvania
| 4 jaar |
Jennifer A. Orange | F | - |
University of Pennsylvania
| 4 jaar |
Jakes Srinivasan | M | - |
University of Pennsylvania
| 2 jaar |
Andrew J. Weil | M | 53 |
University of Pennsylvania
| 4 jaar |
Kevin Kotler | M | 53 |
University of Pennsylvania
| 4 jaar |
Howard Chin | M | - |
University of Pennsylvania
| 4 jaar |
Guy Zaczepinski | M | - |
University of Pennsylvania
| 4 jaar |
Evan S. Melrose | M | 54 |
University of Pennsylvania
| 4 jaar |
Michael Rotgin | M | - |
University of Pennsylvania
| 4 jaar |
Greg Brogger | M | 55 |
University of Pennsylvania
| 4 jaar |
Jonathan I. Grabel | M | - |
University of Pennsylvania
| 4 jaar |
Robert Buccigrossi | M | - |
University of Pennsylvania
| 4 jaar |
Craig Yeshion | M | - |
University of Pennsylvania
| 4 jaar |
Jacqueline Lesage-Krause | F | - |
University of Pennsylvania
| 4 jaar |
Ron Mordechai Lior | M | - |
University of Pennsylvania
| 5 jaar |
David Francis Betten | M | - |
University of Pennsylvania
| 4 jaar |
Adrian Gulich | M | - |
University of Pennsylvania
| 2 jaar |
Adam Borneleit | M | - |
University of Pennsylvania
| 4 jaar |
Nicholas G. Demmo | M | - |
University of Pennsylvania
| 3 jaar |
Misha Ali | M | - |
University of Pennsylvania
| 4 jaar |
Tim Sledge | M | - |
University of Pennsylvania
| 4 jaar |
Allison W. Brady | F | 53 |
University of Pennsylvania
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Bruce Goldsmith
- Persoonlijk netwerk